Results 21 to 30 of about 268,746 (338)

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma

Journal of Immunology Research, 2020
Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis.
John Apostolidis, Ayman Sayyed, Mohammed Darweesh, Panayotis Kaloyannidis, Hani Al Hashmi   +4 more
doaj   +1 more source

Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?

Frontiers in Oncology, 2022
Immune checkpoint inhibitors have improved the survival in patients affected by an increasing number of malignancies, but they may also trigger various autoimmune side-effects, including endocrinopathies.
Agnese Barnabei, Lidia Strigari, Andrea Corsello, Rosa Maria Paragliola, Luca Falzone, Roberto Salvatori, Salvatore Maria Corsello, Salvatore Maria Corsello, Francesco Torino   +8 more
doaj   +1 more source

The role of immune checkpoint inhibitors in the development and treatment of infectious processes [PDF]

Клиническая практика
The incidence and prevalence of oncological diseases, which are the second most frequent cause of death, is steadily increasing among the population of the Russian Federation.
Dilya A. Mustafina, Aisylu N. Bagautdinova, Milyausha M. Zinatullina, NIkita A. Gorbunov, Elvina T. Zainetdinova, Diana I. Bukharmetova, Daniil Yu. Leonov, Aibike G. Pirmagomedova, Anna E. Chernyshova, Maria P. Markhanos, Anna G. Abgaryan, Arina S. Arustamyan, Konstantin S. Chavro, Farzonakhon Mirzojonova   +13 more
doaj   +1 more source

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab

Frontiers in Oncology, 2020
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity.
S. Morteza Seyed Jafari, Laurence Feldmeyer, Robert E. Hunger   +2 more
doaj   +1 more source

SnapShot: Immune Checkpoint Inhibitors

Cancer Cell, 2017
Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance).
Abril-Rodriguez, Gabriel, Ribas, Antoni
openaire   +4 more sources

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity

Journal of Experimental & Clinical Cancer Research, 2021
Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies.
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime   +6 more
doaj   +1 more source

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello, Mazzone, Roberta, Valente, Sergio, Zwergel, Clemens   +3 more
core   +1 more source

A Role of Therapy that Targets Immune Checkpoint Proteins for the Treatment of Melanoma Brain Metastasis, Liver, Breast, Pancreatic Cancer and Pancreatic Adenocarcinoma

مجله كليه طب الكندي, 2022
Checkpoint inhibitors are a type of immune therapy used to treat different types of cancers. These drugs block different checkpoint proteins, for example, CTLA-4, PD-1, and PD-L1 inhibitors.
Smaa Elsayed Mohammed, Basma Aml Youssef, Doaa Alaa Ghonai, Eman Fares Ahmed, Esraa Gharieb Mohammed, Mai Ashraf Abdo, Mai Essam Mohammed, Rana Gharieb Hassan, Reem Mohammed Mohammed, Rofida Ahmed Abd Al-Azeem, Sarah Adel Swelem, Sarah Ouda Salman, Sarah Mohammed Al-aiyq, Toka Taha Taha, Zainab Khalid Moawad   +14 more
doaj   +1 more source

Cardiotoxicity of immune checkpoint inhibitors [PDF]

, 2017
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity.
Allison, Atkins, Azuma, Azuma, Baban, Badros, Bellmunt, Bloom, Borghaei, Boussiotis, Boutros, Brahmer, Brahmer, Bretscher, Brunet, Buchbinder, Cardinale, Cardinale, Chen, Chen, Chen, Cooper, Corsello, Costa, Ding, Dong, Dong, Douglas, Dyck, Eigentler, Fehrenbacher, Francisco, Freeman, Freeman, Gagliani, Gangadhar, Garon, Gay, Geisler, Gibson, Goodman, Gordon, Grabie, Hamanishi, Hamid, Hamo, Han, Hathcock, Heinzerling, Herbst, Herbst, Hodi, Hofmann, Huang, Hurst, Jain, Johnson, Johnson, Johnston, Keir, Khan, Koelzer, Lacouture, Larkin, Lasaro, Latchman, Le Mercier, Le Mercier, Leach, Lesokhin, Lines, Linsley, Linsley, Lucas, Läubli, Mahoney, Martin, Matsuzaki, Menzies, Michot, Mohme, Moslehi, Moynihan, Naidoo, Nayak, Nghiem, Nguyen, Ni, Nishimura, Nishimura, Okamura, Okazaki, Okazaki, Pardoll, Peggs, Pitt, Postow, Powles, Prashanth, Ribas, Rittmeyer, Rizvi, Robert, Robert, Roth, Sakuishi, Semper, Sharma, Sharma, Sheppard, Sivan, Smyth, Spain, Stanietsky, Suter, Tadokoro, Tadokoro, Tarrio, Tivol, Tocchetti, Tocchetti, Topalian, Topalian, Tumeh, Voskens, Vétizou, Wang, Wang, Watanabe, Waterhouse, Weber, Westin, Wing, Wolchok, Woo, Yan, Yeh, Yokosuka, Yu, Yun, Zitvogel   +140 more
core   +1 more source